• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Cancer . Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study

tetano

Editor, Senior Moderator
Eur J Cancer


. 2021 Feb 27;148:359-370.
doi: 10.1016/j.ejca.2021.02.027. Online ahead of print.
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study


Sylvain Ladoire[SUP] 1 [/SUP], Vincent Goussot[SUP] 2 [/SUP], Emilie Redersdorff[SUP] 3 [/SUP], Adele Cueff[SUP] 4 [/SUP], Elise Ballot[SUP] 5 [/SUP], Caroline Truntzer[SUP] 5 [/SUP], Siavoshe Ayati[SUP] 6 [/SUP], Leila Bengrine-Lefevre[SUP] 6 [/SUP], Nathalie Bremaud[SUP] 6 [/SUP], Bruno Coudert[SUP] 6 [/SUP], Isabelle Desmoulins[SUP] 6 [/SUP], Laure Favier[SUP] 6 [/SUP], Cl?a Fraisse[SUP] 6 [/SUP], Jean-David Fumet[SUP] 6 [/SUP], Roxana Hanu[SUP] 6 [/SUP], Audrey Hennequin[SUP] 6 [/SUP], Alice Hervieu[SUP] 6 [/SUP], Silvia Ilie[SUP] 6 [/SUP], Cour?che Kaderbhai[SUP] 6 [/SUP], Aur?lie Lagrange[SUP] 6 [/SUP], Nils Martin[SUP] 6 [/SUP], Irina Mazilu[SUP] 6 [/SUP], Didier Mayeur[SUP] 6 [/SUP], R?mi Palmier[SUP] 6 [/SUP], Anne-Laure Simonet-Lamm[SUP] 6 [/SUP], Julie Vincent[SUP] 6 [/SUP], Sylvie Zanetta[SUP] 6 [/SUP], Laurent Arnould[SUP] 7 [/SUP], Charles Coutant[SUP] 8 [/SUP], Aur?lie Bertaut[SUP] 4 [/SUP], Fran?ois Ghiringhelli[SUP] 9 [/SUP]



Affiliations

Abstract

Background: In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection.
Methods: After the first lockdown, all medical and non-medical staff, as well as all patients attending the medical oncology department were invited to undergo serological testing for SARS-CoV-2 between 11 May and 30 June 2020. All participants were also invited to complete a questionnaire collecting data about their living and working conditions, and for patients, medical management during lockdown.
Findings: A total of 1,674 subjects (663 staff members, 1011 patients) were included. Seroprevalence was low in both staff (1.8%) and patients (1.7%), despite more features of high risk for severe forms among patients. None of the risk factors tested in our analysis (working or living conditions, comorbidities, management characteristics during lockdown) was found to be statistically associated with seroprevalence in either staff or patients. There was no significant difference in the proportion of symptomatic and asymptomatic subjects between staff and patients. Only fever, loss of smell, and loss of taste were significantly more frequent among seropositive patients, in both staff and patients.
Interpretation: We report very low seroprevalence of antibodies against SARS-CoV-2 in the staff (caregiving and non-caregiving) and patients of a large cancer care centre in which strict hygiene, personal protection, and social distancing measures were implemented.

Keywords: Antibody; COVID-19; Cancer center; Cancer patients; Healthcare workers; SARS-COV-2; Serodiagnosis; Serology; Seroprevalence; Staff.
 
Back
Top Bottom